Novartis

Novartis announced the expansion of its community health programs to address heart disease and cancer in underserved communities globally. This initiative is expected to enhance its corporate social responsibility profile and potentially open new market segments in emerging economies and underserved populations.

Novartis has settled a lawsuit with the Estate of Henrietta Lacks regarding the unauthorized use of HeLa cells. The settlement terms are confidential, but it resolves a claim of unjust enrichment, potentially mitigating further legal and reputational risks for Novartis.

Novartis is a key player in the CAR T cell market, actively involved in advancing next-generation therapies to improve treatment outcomes.

Despina Solomonidou, EVP & Global Head - Technical Research & Development at Novartis, will address key sessions at BioAsia 2026.

Novartis, a multinational innovator, may see growth in patient numbers for its therapies in India as the price barrier eases due to the customs duty exemption. Amitabh Dube, Country President and Managing Director of Novartis India, welcomed the announcement.